The subsidiary of Beijing Bohui Innovation Biotechnology Group (300318.SZ) has obtained the drug registration certificate for coagulation factor VIII.

Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced that its holding subsidiary, Bohui Biopharmaceutical (Hebei) Co., Ltd. (hereinafter referred to as "Hebei Bohui"), has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the drug human coagulation factor VIII. This product has a corrective effect on coagulation disorders caused by a lack of human coagulation factor VIII and is mainly used for the prevention and treatment of hemophilia A and bleeding symptoms caused by acquired factor VIII deficiency, as well as for surgical bleeding treatment in these patients. The acquisition of the "Human Coagulation Factor VIII" "Drug Registration Certificate" is a further supplement to the company's products, enriching the company's product line and is of great significance for Hebei Bohui to improve the efficiency of plasma utilization.